Evidence map›Paper›PMID 27401222›Full record

Trial reportThe pharmacogenomics journal2016

Lithium-responsive genes and gene networks in bipolar disorder patient-derived lymphoblastoid cell lines.

M S Breen, C H White, T Shekhtman, K Lin, D Looney, C H Woelk, J R Kelsoe

Abstract readClinical TrialComparative Study
PubMed Publisher
In one paragraph

Trial report in The pharmacogenomics journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
5.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 53 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. RNA Biomarkers in Bipolar Disorder and Response to Mood Stabilizers.International journal of molecular sciences · 2023
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Exploring lithium's transcriptional mechanisms of action in bipolar disorder: a multi-step study.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2020
    Article
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 3 countries.

M S BreenClinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.
C H WhiteDepartment of Medicine, University of California, San Diego, La Jolla, CA, USA.
T ShekhtmanVeterans Administration, San Diego Healthcare System, San Diego, CA, USA.
K LinDepartment of Affective Disorder, Guangzhou Brain Hospital, Guangzhou Medical University, Guangzhou, China.
D LooneyDepartment of Medicine, University of California, San Diego, La Jolla, CA, USA.
C H WoelkClinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.
J R KelsoeDepartment of Medicine, University of California, San Diego, La Jolla, CA, USA.
University of California, San Diego · USGuangzhou Medical University · CNIcahn School of Medicine at Mount Sinai · USUniversity of Southampton · GBVA San Diego Healthcare System · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lithium (Li) is the mainstay mood stabilizer for the treatment of bipolar disorder (BD), although its mode of action is not yet fully understood nor is it effective in every patient. We sought to elucidate the mechanism of action of Li and to identify surrogate outcome markers that can be used to better understand its therapeutic effects in BD patients classified as good (responders) and poor responders (nonresponders) to Li treatment. To accomplish these goals, RNA-sequencing gene expression profiles of lymphoblastoid cell lines (LCLs) were compared between BD Li responders and nonresponders with healthy controls before and after treatment. Several Li-responsive gene coexpression networks were discovered indicating widespread effects of Li on diverse cellular signaling systems including apoptosis and defense response pathways, protein processing and response to endoplasmic reticulum stress. Individual gene markers were also identified, differing in response to Li between BD responders and nonresponders, involved in processes of cell cycle and nucleotide excision repair that may explain part of the heterogeneity in clinical response to treatment. Results further indicated a Li gene expression signature similar to that observed with clonidine treatment, an α2-adrenoceptor agonist. These findings provide a detailed mechanism of Li in LCLs and highlight putative surrogate outcome markers that may permit for advanced treatment decisions to be made and for facilitating recovery in BD patients.

Indexed as

Pharmacogenomic VariantsAdultAffectAntipsychotic AgentsBipolar DisorderCell LineDrug ResistanceGene Expression ProfilingGene Expression RegulationGene Regulatory NetworksGenetic MarkersGenotypeHumansLithium CompoundsLymphocytesMaleAntipsychotic AgentsGenetic MarkersLithium Compounds

Identifiers

PMID27401222
OpenAlexW2468590741

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.